In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
All content for Divergent States is the property of Divergent States and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
Alli Schaper: Microdosing, Mushrooms, and Policy Reform
Divergent States
1 hour 5 minutes
7 months ago
Alli Schaper: Microdosing, Mushrooms, and Policy Reform
In this episode of Divergent States, we sit down with Alli Schaper, CEO of Supermush and co-founder of the Microdosing Collective, to explore the evolving world of functional and psychedelic mushrooms. Alli shares her journey into microdosing advocacy, the challenges of navigating the gray market for psychedelics, and the urgent push for policy reform to ensure safe, legal access. We dive into the science behind microdosing, its profound benefits for mental health, creativity, and even athlet...
Divergent States
In this episode of Divergent States, 3L1T3 sits down with Betty Aldworth, the new co-president of MAPS, as she steps into shared leadership with Ismail Ali following Rick Doblin’s four-decade run. Betty brings decades of experience in drug policy reform, from Colorado’s 2012 cannabis legalization campaign to leading Students for Sensible Drug Policy, and now helps guide MAPS through one of the movement’s most pivotal moments: the FDA’s rejection of Lycos Therapeutics’ MDMA-assisted therapy ap...
